01 · Set your context
Experience level, goals, and preferences
Selected schedule
Scheduled use only. This view does not model clearance or establish safety.
02 · Add compounds
Click any compound to add it to your cycle
1-Testosterone
Community: 300–400 mg/week total · Injection interval depends on ester; no fixed count in this claim · context required
4-Androstenediol
PED-use amount not established here; Human androstenediol research exists; identity/formulation review pending
ACP-105
Reference review incomplete for this profile
Anadrol
Community: 50–100 mg/day total · Source specifies a daily total, not how many administrations per day · source reference
Anavar
Community: 30–50 mg/day total · Source specifies a daily total, not how many administrations per day · source reference
Andarine
PED-use amount not established here; FDA warning letter names S-4 Andarine among marketed unapproved products.
Arimidex
Community: 0.5 mg/administration · Every 3 days OR every 3.5 days · context required
Aromasin
Community: 12.5 mg/administration · Every 3 days OR every 3.5 days · context required
Ashwagandha
PED-use amount not established here; Product-specific studied references may be shown after extract matching
Astragalus
PED-use amount not established here; Condition/formulation-specific evidence; no universal value
BPC-157
PED-use amount not established here; FDA describes limited human safety information and immunogenicity concerns.
Cabergoline
PED-use amount not established here; scoped source context available
Cardarine
PED-use amount not established here; GW501516 was investigated for lipid endpoints in two related clinical studies.
Citrus Bergamot
PED-use amount not established here; Product-specific trial exposure available
CJC-1295
PED-use amount not established here; Two short controlled trials measured endocrine responses, not a universal treatment program.
Clenbuterol
PED-use amount not established here; Community source exists; documented harm; no universal value
Clomid
PED-use amount not established here; Source references available; context required
Clomiphene
PED-use amount not established here; Source references available; context required
Dianabol
Community: 30–50 mg/day total · Source specifies a daily total, not how many administrations per day · source reference
Dutasteride
PED-use amount not established here; Source references available; context required
Epistane
PED-use amount not established here; Source identity conflict; primary adverse-event evidence available
Equipoise
Community: 400–600 mg/week total · Weekly total; administration frequency is a separate discussion · context required
Finasteride
PED-use amount not established here; scoped source context available
FOXO4-DRI
PED-use amount not established here; Aging-mouse and endothelial-cell experiments investigated a proposed senolytic mechanism.
GHRP-2
PED-use amount not established here; FDA reports serious events with unestablished causality and peptide-quality concerns.
GHRP-6
PED-use amount not established here; FDA cites limited safety data and concerns involving cortisol and glucose.
Glucosamine
PED-use amount not established here; Osteoarthritis research exists; salt/formulation and context required
Glycine
PED-use amount not established here; Studied oral bedtime exposure available; small-study context
Halotestin
Community: 20–50 mg/day total · Daily total; source separately describes divided daily amounts · context required
HCG
Community: 250 IU/administration · Every other day · context required
Hexarelin
PED-use amount not established here; Small acute experiment measured growth-hormone response.
hGH
PED-use amount not established here; Somatropin labeling distinguishes diagnoses, age groups and individualized response monitoring.
HGH Fragment 176-191
Reference review incomplete for this profile
HMG
PED-use amount not established here; Source references available; context required
Humalog Insulin
PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.
Humulin R
PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.
IGF-1 DES
Reference review incomplete for this profile
IGF-1 LR3
Reference review incomplete for this profile
Ipamorelin
PED-use amount not established here; FDA notes serious events in intravenous research and insufficient safety data for other injectable routes.
ITPP
PED-use amount not established here; Early-phase oncology exposure exists; no universal value
Lantus Insulin
PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.
Letrozole
PED-use amount not established here; Source references available; context required
LGD-3303
Reference review incomplete for this profile
LGD-4033
PED-use amount not established here; Short controlled human trial examined safety, pharmacokinetics and exploratory physical outcomes.
Masteron
Community: 300–500 mg/week total · Source also gives daily/EOD administrations with a separate range · context required
Melanotan II
PED-use amount not established here; FDA lists serious reported adverse events; causation and frequency are not established.
Mesterolone
Community: 25–100 mg/day total · Daily total; source discusses splitting as optional · context required
MGF
PED-use amount not established here; The FDA entry concerns PEG-MGF, not every substance called MGF.
Mibolerone
PED-use amount not established here; Community source exists; veterinary/preclinical lineage; no universal value
MK-677
PED-use amount not established here; Older-adult trial measured body composition; increased fat-free mass did not improve strength or function.
MOTS-c
PED-use amount not established here; FDA reports no identified human exposure data and insufficient safety information.
M-Tren
PED-use amount not established here; Source exists; toxicity evidence; no universal value
NAD+
PED-use amount not established here; Pilot infusion evidence exists; wellness efficacy and other routes unresolved
Nandrolone
Community: 400 mg/basis unspecified in source · Time denominator absent in the amount sentence; frequency discussion is separate · context required
Novolog Insulin
PED-use amount not established here; The label requires individualized treatment based on metabolic needs, glucose results and glycemic goals.
Omega-3 EPA/DHA
PED-use amount not established here; EPA/DHA-specific dietary or clinical reference; not fish-oil mass
Ostarine
PED-use amount not established here; Controlled phase 2 study provides context for enobosarm exposure in older adults.
PE-22-28
PED-use amount not established here; Cell experiments and mouse behavioral studies provide preclinical context.
Primo
Community: 80–150 mg/day total · Source says at least once daily but does not define a fixed count · context required
PT-141
PED-use amount not established here; scoped source context available
RAD-140
PED-use amount not established here; Official record verifies a first-in-human oncology trial.
Retatrutide
PED-use amount not established here; Historical phase 2 trial has population-specific exposure context; current FDA page still describes it as unapproved.
S-23
PED-use amount not established here; Reviewed primary study concerns male contraception in rats.
Semaglutide
PED-use amount not established here; scoped source context available
SR9009
PED-use amount not established here; Mouse/cell studies support experimental context and also question exclusive REV-ERB specificity.
Superdrol
Community: 10–30 mg/day total · Daily total; opening Average Dose section · context required
Tamoxifen
PED-use amount not established here; Source references available; context required
TB-500
PED-use amount not established here; FDA reports no identified human exposure data for the specified fragment.
Tesamorelin
PED-use amount not established here; Label-backed reference must retain the exact product and medical indication.
Testosterone
Community: 500 mg/week total · Source lists E3D OR E3.5D alongside this weekly total · context required
Tirzepatide
PED-use amount not established here; scoped source context available
Trenbolone
Community: 50 mg/day total · Daily total; acetate-specific community claim · context required
Trestolone
PED-use amount not established here; Community reference exists; experimental; implant research not injectable-dose support
TUDCA
PED-use amount not established here; Source references available; context required
Turinabol
Community: 40–50 mg/day total · Source specifies a daily total, not how many administrations per day · source reference
UDCA
PED-use amount not established here; Source references available; context required
Winstrol
Community: 25–100 mg/day total · Daily amount; oral splitting and injectable cadence discussed separately · context required
YK-11
PED-use amount not established here; Cell study reports follistatin expression and myogenic differentiation.
Yohimbine
PED-use amount not established here; Formulation-specific evidence review needed
Androgenic Load
Safety Warnings
Add compounds to see relevant warnings.